Expecting windfall from wave of cancer patients, Pfizer leases huge property in San Diego for research and development of cancer drugs
By Ava Grace // Mar 20, 2024

The oncology division of pharmaceutical giant Pfizer has leased a huge property in San Diego as part of its efforts to redefine itself as a cancer-drug powerhouse.

This comes amid a noticeable increase in the number of people receiving cancer treatment in recent years, particularly after the global rollout of Wuhan coronavirus (COVID-19) vaccines. (Related: Vaccine side effect? Swiss health insurer's data shows 73% increase in people receiving cancer treatment since 2020.)

Bloomberg News reported that Pfizer agreed to a 15-year lease for 230,000 square feet at the Torrey View life sciences complex in Silicon Beach, citing a statement by developer Breakthrough Properties. The drug manufacturer will occupy two research and development buildings at the 10-acre campus, which is nearing completion.

According to the statement, the property offers "high-quality lab infrastructure" along with a 400-person conference facility, ocean views and campus amenities such as a fitness center and pickleball court.

"Torrey View is an ideal campus for innovation," Breakthrough Properties CEO Dan Belldegrun said in the March 15 statement. "Breakthrough is proud to support the Pfizer Oncology team as they continue to discover and develop next-generation therapies."

The statement didn't disclose the financial terms of the lease. But based on data from CBRE Group Inc. on average asking rents in the area, the total for the 15-year deal would be about $290 million.

According to CBRE, the Pfizer lease is more than double the size of any life-science deal in the San Diego area in 2023. That year, the largest single tenant was medical test kit maker Acon taking 97,162 square feet of real estate space.

Human knowledge is under attack! Governments and powerful corporations are using censorship to wipe out humanity's knowledge base about nutrition, herbs, self-reliance, natural immunity, food production, preparedness and much more. We are preserving human knowledge using AI technology while building the infrastructure of human freedom. Use our decentralized, blockchain-based, uncensorable free speech platform at Brighteon.io. Explore our free, downloadable generative AI tools at Brighteon.AI. Support our efforts to build the infrastructure of human freedom by shopping at HealthRangerStore.com, featuring lab-tested, certified organic, non-GMO foods and nutritional solutions.

The company added that San Diego is one of the largest centers for life-science research after Boston and the San Francisco Bay Area. However, demand for offices slowed down in 2023 as venture capital funding decreased.

Pfizer's pivot away from Wuhan coronavirus (COVID-19) products and into cancer drugs comes at a crucial time. The New York-based drug firm has been trying to shore up investor sentiment after its shares fell more than 40 percent in 2023. This translated to an erasure of more than $100 billion in Pfizer's market value.

Pfizer shifts to oncology drugs after COVID-19

According to CNBC, Pfizer is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its COVID-19 business. Its acquisition of cancer drug manufacturer Seagen for $43 billion proves that it is ready to move on from COVID-19. With the Seagen product line incorporated into Pfizer, the latter is ready to produce at least eight cancer drugs by 2030 and 60 different experimental drugs on the pipeline. (Related: NEVER FORGET: Pfizer RIGGED scientific studies, promoted off-label use of its epilepsy drug Neurontin to hit sales targets.)

However, some analysts have noted that it might take a few years for some of Pfizer's cancer drugs in mid-stage development to show pivotal clinical trial data and become less risky. But it's not just drugs in the works; Pfizer's existing oncology portfolio is also facing some competitive pressure.

Revenue from the blockbuster breast cancer drug Ibrance and prostate cancer treatment Xtandi, which Pfizer shares with Astellas Pharma, has declined over the past year. Both drugs are expected to lose market exclusivity in 2027.

Aside from this, Pfizer disappointed Wall Street last year with the underwhelming launch of a new RSV shot, a twice-daily weight loss pill that fell short in clinical trials and a 2024 forecast that missed expectations. The company has launched a $4 billion cost-cutting program, laying off hundreds of employees and shaving down its research and development spending.

Visit BigPharmaNews.com for more stories about Pfizer.

Watch this video about Pfizer's COVID-19 vaccines containing toxic and carcinogenic DNA.

This video is from the Rick Langley channel on Brighteon.com.

More related stories:

Health Canada confirms that Pfizer COVID-19 injections contain SV40 DNA sequence that can cause CANCER.

Scientist says Pfizer INTENTIONALLY DECEIVED regulators about COVID-19 vaccine contamination.

FRESHLY OVERLAID graphene oxide “nanobots” found in Pfizer COVID-19 vaccines.

RSV introduced into population by polio vaccines; now Pfizer’s RSV vaccines risk harming, killing people.

Pfizer sued by GSK over claims that the US drug giant stole “key elements” of the UK firm’s RSV injection.

Sources include:

Bloomberg.com

Brighteon.com



Take Action:
Support NewsTarget by linking to this article from your website.
Permalink to this article:
Copy
Embed article link:
Copy
Reprinting this article:
Non-commercial use is permitted with credit to NewsTarget.com (including a clickable link).
Please contact us for more information.
Free Email Alerts
Get independent news alerts on natural cures, food lab tests, cannabis medicine, science, robotics, drones, privacy and more.

NewsTarget.com © 2022 All Rights Reserved. All content posted on this site is commentary or opinion and is protected under Free Speech. NewsTarget.com is not responsible for content written by contributing authors. The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. NewsTarget.com assumes no responsibility for the use or misuse of this material. Your use of this website indicates your agreement to these terms and those published on this site. All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.

This site uses cookies
News Target uses cookies to improve your experience on our site. By using this site, you agree to our privacy policy.
Learn More
Close
Get 100% real, uncensored news delivered straight to your inbox
You can unsubscribe at any time. Your email privacy is completely protected.